Scholars@Duke

• Background
• 

  Education, Training, & Certifications

  • Hematology-Oncology Fellowship, Medicine, Duke University School of Medicine 2014 - 2017
  • Internal Medicine Residency, Baylor College of Medicine 2011 - 2014
  • MD./PhD., University of Texas MD Anderson Cancer Center 2011
• 

  Duke Appointment History

  • Assistant Professor of Medicine, Medicine, Medical Oncology, Medicine 2018 - 2020
  • Medical Instructor in the Department of Medicine, Medicine, Medical Oncology, Medicine 2017 - 2018
• Research
• 

  Selected Grants

  • A Phase 2 Study in First Line Metastatic or Unresectable, Recurrent Head and Neck Squamous Cell Carcinoma to Evaluate Intratumoral MK-1454 in Combination with IV Pembrolizumab vs IV Pembrolizumab Monotherapy awarded by Merck Sharp & Dohme 2021 - 2026
  • Arcus PANTHEON awarded by Arcus Biosciences 2020 - 2026
  • A Phase II, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Trastuzumab Deruxtecan (T-DXd, DS-8201a) for the Treatment of Selected HER2-expressing Tumors (DESTINY-PanTumor02) awarded by AstraZeneca Pharmaceuticals, LP 2021 - 2026
  • A Phase 1, Open-Label, Multiple-Ascending Dose Study of the Safety and Tolerability of CTX-471 in Patients with Inadequate Responses to PD-1/PD-L1 Checkpoint Inhibitors in Metastatic or Locally Advanced Malignancies awarded by Compass Therapeutics 2020 - 2025
  • MK-7902-009-00 LEAP-009 awarded by Merck Sharp & Dohme 2020 - 2025
  • RGN-1901 awarded by Regeneron Pharmaceuticals, Inc. 2020 - 2025
  • Rutgers TVEC+ISS in SCCS awarded by Rutgers, The State University of New Jersey 2020 - 2025
  • LEAP-MK-7902-010 awarded by Merck Sharp & Dohme 2020 - 2025
  • A Phase 1 Multiple-Dose Study to Evaluate the Safety and Tolerability of XmAb®23104 in Subjects with Selected Advanced Solid Tumors (DUET-3) awarded by Xencor, Inc 2019 - 2024
  • Genmab GCT1021-01 awarded by Genmab A/S 2018 - 2023
  • A Phase I, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-Tumor Activity of Ascending Doses of AZD4635 Both as Monotherapy and in Combination with Durvalumab in Patients with Advanced Solid Ma awarded by AstraZeneca Pharmaceuticals, LP 2017 - 2022
  • A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Cabozantinib (XL184) in Subjects with Radioiodine-Refractory Differentiated Thyroid Cancer Who Have Progressed after Prior VEGFR-Targeted Therapy awarded by Exelixis, Inc 2019 - 2022
  • Analysis of AXL expression in radiation-resistant head and neck squamous cells carcinoma (HNSCC) awarded by Genmab A/S 2020 - 2022
  • An Open-Label Phase 1B/2 Study to Evaluate the Safety and Efficacy of Tabelecleucel in Combination with Pembrolizumab in Subjects with Platinum-pretreated, Recurrent/Metastatic Epstein Barr Virus Associated Nasopharyngeal Carcinoma awarded by Atara Biotherapeutics, Inc. 2019 - 2021
  • Duke-UNC-Wash U Partnership for Early Phase Clinical Trials in Cancer awarded by National Institutes of Health 2014 - 2021
  • RIFTOS MKI (Bayer Observational Study) Number 17852 NX1401 awarded by Bayer Healthcare Pharmaceuticals Inc 2015 - 2020
  • Anti-Tumor Effects of locally and Systemically Administered EZN-2279 monotherapy in a murine model of Colorectal Carcinoma awarded by Leadiant Biosciences, Inc. 2017 - 2018
• 

  External Relationships

  • AstraZeneca
  • Blueprint Medicines
  • Cancer Support Community
  • Compass Therapeutics
  • Exelixis, Inc.
  • Merck
  • Xencor
• Publications & Artistic Works
• 

  Selected Publications

  • Academic Articles

    • Choe, Jennifer, and Richard Riedel. “Making progress in a rare disease: emerging therapeutics in soft tissue sarcomas.” F1000res 7 (2018). https://doi.org/10.12688/f1000research.15868.1.
       Full Text  Link to Item
    • Choe, Jennifer H., Brian J. Andonian, Grace J. Kim, and April Ks Salama. “Autoimmune meningoencephalitis in a melanoma patient treated with ipilimumab.” Immunotherapy 8, no. 10 (October 2016): 1163–67. https://doi.org/10.2217/imt-2016-0058.
       Full Text  Link to Item
    • Hong, David S., Jennifer Hsing Choe, Aung Naing, Jennifer J. Wheler, Gerald S. Falchook, Sarina Piha-Paul, Stacy L. Moulder, et al. “A phase 1 study of gemcitabine combined with dasatinib in patients with advanced solid tumors.” Investigational New Drugs 31, no. 4 (August 2013): 918–26. https://doi.org/10.1007/s10637-012-9898-3.
       Full Text

  • Book Sections

    • Choe, J. H., and J. L. Abbruzzese. “Emerging therapeutic targets in pancreatic adenocarcinoma.” In Pancreatic Cancer, 1613–41, 2018. https://doi.org/10.1007/978-1-4939-7193-0_92.
       Full Text
    • Jacobs, C. D., M. J. Moravan, J. Choe, R. Kahmke, Y. Mowery, and J. K. Salama. “Oral cavity cancer: Diagnosis and treatment.” In Encyclopedia of Cancer, 131–68, 2018. https://doi.org/10.1016/B978-0-12-801238-3.65316-3.
       Full Text

  • Conference Papers

    • Lim, Emerson A., Todd Michael Bauer, Manish R. Patel, Gerald Steven Falchook, Janet L. Karlix, Jennifer Hsing Choe, Daniel J. George, et al. “A phase I, open-label, multicenter study to assess the safety, pharmacokinetics, and preliminary antitumor activity of AZD4635 both as monotherapy and in combination in patients with advanced solid malignancies: Results from prostate cancer patients (NCT02740985).” In Journal of Clinical Oncology, Vol. 38, 2020.
       Link to Item
    • Siu, Lillian L., Joshua Bauml, Douglas Adkins, A Dimitrios Colevas, Cesar Augusto Perez, Jennifer Hsing Choe, Yang Zhang, et al. “Tabelecleucel in combination with pembrolizumab (Pembro) in platinum-pretreated, recurrent/metastatic Epstein-Barr virus (EBV)-positive nasopharyngeal carcinoma (EBV+NPC).” In Journal of Clinical Oncology, 37:TPS6092–TPS6092. American Society of Clinical Oncology (ASCO), 2019. https://doi.org/10.1200/jco.2019.37.15_suppl.tps6092.
       Full Text
    • Olivo, Robert E., Melanie Goebel, Jennifer Choe, David Howell, David Butterly, and John K. Roberts. “C3 GLOMERULONEPHRITIS WITH MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE (MGUS).” In American Journal of Kidney Diseases, 67:A81–A81. W B SAUNDERS CO-ELSEVIER INC, 2016.
       Link to Item

Some information on this profile has been compiled automatically from Duke databases and external sources. (Our About page explains how this works.) If you see a problem with the information, please write to Scholars@Duke and let us know. We will reply promptly.